Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab
AbstractOver the last ten years, the treatment of seronegative spondyloarthropathies has changed dramatically with the introduction of the anti-tumor necrosis factor alpha (TNFα) agents. Nevertheless, there is a growing number of studies describing several adverse reactions in patients treated with biological agents. In the present report we describe the case of a 22-year-old male patient with ankylosing spondylitis who developed a “paradoxic” adverse reaction, while receiving infliximab.
- Abstract views: 880
- PDF: 472
Copyright (c) 1970 M. Gutierrez, A. Becciolini, C. Bertolazzi, L. Di Geso, M. Tardella, A. Ariani, E. Filippucci, W. Grassi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.